At-equity investees’ higher contribution
19/11/23 -"We have updated our model at the at-equity associates line as it looks as if Vifor Fresenius Medical Care Pharma (JV with former Galenica / CSL Vifor) makes greater contributions due to higher sales ..."
Pages
57
Language
English
Published on
19/11/23
You may also be interested by these reports :
06/12/23
Coloplast reported Q4 23 organic revenue growth of 8% as a strong performance in Voice & Respiratory and Ostomy was partially offset by a weaker ...
06/12/23
To account for the material impact from FX headwinds, we have revised down our near-term estimates. Nonetheless, the firm’s operational performance ...
06/12/23
Fresenius has decided to accept the €300m (of which ~70m had already been taken) from the German government, which is the relief package to ...
01/12/23
We have maintained our assumption and the company’s plan of a €300m capital increase to be completed in H1 24, but with an expected subscription ...